Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

K. Muro, F. Lordick, T. Tsushima, G. Pentheroudakis, E. Baba, Z. Lu, B. C. Cho, I. M. Nor, M. Ng, L. T. Chen, K. Kato, J. Li, M. H. Ryu, W. I. Wan Zamaniah, W. P. Yong, K. H. Yeh, T. E. Nakajima, K. Shitara, H. Kawakami, Y. NaritaT. Yoshino, E. Van Cutsem, E. Martinelli, E. C. Smyth, D. Arnold, H. Minami, J. Tabernero, J. Y. Douillard

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/ locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

Original languageEnglish
Pages (from-to)34-43
Number of pages10
JournalAnnals of Oncology
Volume30
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Medical Oncology
Practice Management
Singapore
Esophageal Neoplasms
Practice Guidelines
Guidelines
Therapeutics
Malaysia
Expert Testimony
Politics
Korea
Disease Management
Taiwan
China
Japan
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Muro, K. ; Lordick, F. ; Tsushima, T. ; Pentheroudakis, G. ; Baba, E. ; Lu, Z. ; Cho, B. C. ; Nor, I. M. ; Ng, M. ; Chen, L. T. ; Kato, K. ; Li, J. ; Ryu, M. H. ; Wan Zamaniah, W. I. ; Yong, W. P. ; Yeh, K. H. ; Nakajima, T. E. ; Shitara, K. ; Kawakami, H. ; Narita, Y. ; Yoshino, T. ; Van Cutsem, E. ; Martinelli, E. ; Smyth, E. C. ; Arnold, D. ; Minami, H. ; Tabernero, J. ; Douillard, J. Y. / Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer : A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. In: Annals of Oncology. 2019 ; Vol. 30, No. 1. pp. 34-43.
@article{9280be8cc39a439d8dde0e13da6de731,
title = "Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS",
abstract = "The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/ locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.",
author = "K. Muro and F. Lordick and T. Tsushima and G. Pentheroudakis and E. Baba and Z. Lu and Cho, {B. C.} and Nor, {I. M.} and M. Ng and Chen, {L. T.} and K. Kato and J. Li and Ryu, {M. H.} and {Wan Zamaniah}, {W. I.} and Yong, {W. P.} and Yeh, {K. H.} and Nakajima, {T. E.} and K. Shitara and H. Kawakami and Y. Narita and T. Yoshino and {Van Cutsem}, E. and E. Martinelli and Smyth, {E. C.} and D. Arnold and H. Minami and J. Tabernero and Douillard, {J. Y.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/annonc/mdy498",
language = "English",
volume = "30",
pages = "34--43",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

Muro, K, Lordick, F, Tsushima, T, Pentheroudakis, G, Baba, E, Lu, Z, Cho, BC, Nor, IM, Ng, M, Chen, LT, Kato, K, Li, J, Ryu, MH, Wan Zamaniah, WI, Yong, WP, Yeh, KH, Nakajima, TE, Shitara, K, Kawakami, H, Narita, Y, Yoshino, T, Van Cutsem, E, Martinelli, E, Smyth, EC, Arnold, D, Minami, H, Tabernero, J & Douillard, JY 2019, 'Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS', Annals of Oncology, vol. 30, no. 1, pp. 34-43. https://doi.org/10.1093/annonc/mdy498

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer : A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. / Muro, K.; Lordick, F.; Tsushima, T.; Pentheroudakis, G.; Baba, E.; Lu, Z.; Cho, B. C.; Nor, I. M.; Ng, M.; Chen, L. T.; Kato, K.; Li, J.; Ryu, M. H.; Wan Zamaniah, W. I.; Yong, W. P.; Yeh, K. H.; Nakajima, T. E.; Shitara, K.; Kawakami, H.; Narita, Y.; Yoshino, T.; Van Cutsem, E.; Martinelli, E.; Smyth, E. C.; Arnold, D.; Minami, H.; Tabernero, J.; Douillard, J. Y.

In: Annals of Oncology, Vol. 30, No. 1, 01.01.2019, p. 34-43.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer

T2 - A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

AU - Muro, K.

AU - Lordick, F.

AU - Tsushima, T.

AU - Pentheroudakis, G.

AU - Baba, E.

AU - Lu, Z.

AU - Cho, B. C.

AU - Nor, I. M.

AU - Ng, M.

AU - Chen, L. T.

AU - Kato, K.

AU - Li, J.

AU - Ryu, M. H.

AU - Wan Zamaniah, W. I.

AU - Yong, W. P.

AU - Yeh, K. H.

AU - Nakajima, T. E.

AU - Shitara, K.

AU - Kawakami, H.

AU - Narita, Y.

AU - Yoshino, T.

AU - Van Cutsem, E.

AU - Martinelli, E.

AU - Smyth, E. C.

AU - Arnold, D.

AU - Minami, H.

AU - Tabernero, J.

AU - Douillard, J. Y.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/ locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

AB - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/ locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

UR - http://www.scopus.com/inward/record.url?scp=85060182066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060182066&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy498

DO - 10.1093/annonc/mdy498

M3 - Article

C2 - 30475943

AN - SCOPUS:85060182066

VL - 30

SP - 34

EP - 43

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -